A Randomized Clinical Trial of ab Interno Canaloplasty and Trabeculotomy With the OMNI Surgical System Compared to Standard Medical Treatment in Pseudophakic Patients With Primary Open Angle Glaucoma

A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment in Pseudophakic Patients with Primary Open Angle Glaucoma (EVOLVE)

Start Date30 Jun 2024

Sponsor / Collaborator

Sight Sciences, Inc.

CTRI/2024/04/065773 / Not yet recruitingPhase 2/3

a comparative study of the efficacy of the topical triamcinolone acetonide versus topical latanoprost in combination with microneedling and narrowband ultraviolet B phototherapy in the treatment of vitiligo - NIL

Start Date15 May 2024

Sponsor / Collaborator-

NCT06239324 / RecruitingPhase 1/2

Evaluation of Latanoprost Combined With Fractional Erbium- YAG Laser Versus Microneedling in Alopecia Areata Treatment

Alopecia areata (AA) an autoimmune disorder of hair follicles results in varying degrees of scalp, facial and body hair loss.
Clinically, patients' presentation varies from patchy circumscribed scalp involvement to total body and scalp hair loss affects up to 2% of the general population.
The exact pathobiology of AA has still remained elusive, while the common theory is the collapse of the immune privilege of the hair follicle caused by immunological mechanism. Multiple genetic, environment factors and psychological stress contribute to the pathogenesis of Alopecia Areata .
Recent insights into the pathogenesis of AA have led to the development of new treatment strategies, such as Janus kinase inhibitors, biologics and several small molecular agents. In addition, modern therapies for AA, including antihistamines, platelet-rich plasma injection

Start Date01 Feb 2024

Sponsor / Collaborator

Egymedicalpedia

100 Clinical Results associated with Latanoprost

100 Translational Medicine associated with Latanoprost

100 Patents (Medical) associated with Latanoprost

2,030

Literatures (Medical) associated with Latanoprost

01 Mar 2024·Acta ophthalmologica

How latanoprost changed glaucoma management

Review

Author: Oddone, Francesco ; Gugleta, Konstantin ; Gandolfi, Stefano ; Cordeiro, Maria Francesca ; Normando, Eduardo M

Abstract:

Glaucoma is currently considered one of the leading causes of severe visual impairment and blindness worldwide. Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, with an entirely new mechanism of action from that of the antiglaucoma drugs used up to that time was a very important milestone. Since then, due mainly to their efficacy, limited systemic side effects and once daily dosing, prostaglandin analogues (PGAs) have become as the first‐choice treatment for primary open‐angle glaucoma. PGAs are in general terms well tolerated, although they are associated with several mild to moderate ocular and periocular adverse events. Among them, conjunctival hyperemia, eyelash changes, eyelid pigmentation, iris pigmentation and hypertrichosis around the eyes are the most prevalent. The objective of this paper is to review the role of PGAs in the treatment of glaucoma over the 25 years since the launch of Latanoprost and their impact on clinical practice outcomes.

01 Mar 2024·Acta ophthalmologica

Persistence and adherence with Latanoprost: A Danish register‐based cohort study in older patients with glaucoma

Article

Author: Kolko, Miriam ; Amiri, Diva ; Sessa, Maurizio ; Andersen, Morten

Abstract:

Purpose:

This study aims to assess the association between switching patterns and adherence/persistence in Danish patients over the age of 65, who started their first‐ever glaucoma treatment with latanoprost eye drops.

Methods:

Patients were assigned to three different cohorts: (1) switchers, (2) non‐switchers, and (3) preservative‐free latanoprost (Monoprost®) users. Patients were followed for 1 year until the end of data coverage or censoring. Study covariates were used to compute the propensity score. In the adjusted analysis, the propensity score was added to the model as an independent variable. The Cox regression model was used to calculate the hazard ratio (HR) of discontinuation for the three cohorts (the non‐switchers cohort was the reference level) in both adjusted and unadjusted analyses.

Results:

Non‐switchers had a statistically significant lower adherence (proportion of days covered, PDC 92%) than switchers (PDC 96%; p < 0.001) and users of Monoprost® (PDC 99%; p < 0.001). Switchers had a 53% lower risk of treatment discontinuation compared to the reference group within 1 year after the first redemption of latanoprost in both unadjusted (HR 0.47; 95% Confidence interval, 95% CI: 0.41–0.53; p < 0.001) and adjusted (HR 0.47; 95% CI: 0.42–0.53; p < 0.001) analyses. In comparison to the non‐switchers, Monoprost® users had a 78% lower risk for the above result in both unadjusted (HR 0.22; 95% CI: 0.17–0.28; p < 0.001) and adjusted (HR 0.22; 95% CI: 0.17–0.29; p < 0.001) analyses.

Conclusion:

This study found increased adherence and persistence in latanoprost users among those who redeemed preservative‐free latanoprost (Monoprost®) and among those who switched between different latanoprost formulations.

01 Feb 2024·Current opinion in pharmacology

Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review

Review

Author: Anter, Abdelrahman M ; Bhattacharya, Sanjoy K ; Arcuri, Jennifer ; Benitez, Betsy

Recent advancements in prostaglandin analogs (PGAs) have reinforced their role in managing intraocular pressure (IOP). Latanoprost excels in 24-h IOP control, while various PGAs offer similar effectiveness and side effects, generic PGAs perform as well as branded ones, and a notable IOP rise observed upon PGA discontinuation. Formulations with or without preservatives show comparable IOP reduction and adherence, often surpassing benzalkonium chloride (BAK)-preserved options. Emergent PGAs, such as latanoprostene bunod, fixed-dose netarsudil combined with latanoprost, and omidenepag Isopropyl, offer enhanced or non-inferior IOP reduction. The bimatoprost implant introduces a novel administration method with effective IOP reduction. These developments underscore ongoing progress in PGA-focused ophthalmological research. This article offers a comprehensive review of available prostanoid analogs and explores new developments.

News (Medical) associated with Latanoprost

29 Apr 2024

·www.biospace.com

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

21 Poster Presentations include Evaluations of Consumer, Pharmaceutical, Surgical and Vision Care Products and Pipeline Programs, Including a Novel Dry Eye Nutritional Supplement VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology Annual Meeting, which will take place in Seattle May 5-9, 2024. The posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the company’s broad eye care portfolio, as well as pipeline innovations. These include a novel daily nutritional supplement formulated to address dry eye symptoms, which is the focus of two posters as well as a paper published recently in Frontiers in Ophthalmology. “We’re focused on supporting research that advances scientific knowledge of our products and fosters the development of new innovations to serve the holistic needs of eye care professionals and consumers,” said Yehia Hashad, MD, executive vice president, Research & Development and chief medical officer, Bausch + Lomb. “The breadth of data being presented at this meeting, as well as the recent publication evaluating our novel nutritional supplement for dry eyes, Blink™ NutriTears®, underscore this ongoing commitment.” Following is a complete list of titles and lead authors for each of these posters: “Analysis of Glare and its Impact on Retinal Image Quality in Intraocular lenses.” Hosten et al. “A Natural Language Processing Approach to Identify Patients with Uveitic Macular Edema in the IRIS® Registry.” Jin et al. “Clinical Evaluation of a Multi-Ingredient Oral Supplement on Dry Eye Symptoms and Tear Volume.” Barbour et al. “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.” Yassine et al. “Comparison of Clinical Studies from the US and India of a Multi-Ingredient Oral Supplement.” Ryan et al. “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an Existing Lubricating Eye Drop.” Morrow et al. “Development of an In Vitro Assay to Evaluate the Antioxidant Effects of Erythritol and Glycerin in Human Corneal Epithelial Cells.” VanDerMeid et al. “Effects of Perfluorohexyloctane on the Ocular Pharmacokinetics of Latanoprost and Prednisolone Acetate After Topical Administration to Rabbits.” Cavet et al. “Effects of Perfluorohexyloctane on Corneal Healing in an Ex Vivo Study of Rabbit Corneas.” Alexander et al. “Efficacy of Perfluorohexyloctane Ophthalmic Solution in Patients with Dry Eye Disease Stratified by Baseline Severity.” Sheppard et al. “Enhancing Silicone Oil Removal Efficiency: A Comparative Study of Ultrasonic Vitrectomy Handpieces and Conventional Methods.” Higgins et al. “Evaluating a Novel Contact Solution Among Hydrogen Peroxide Lens Care Users.” Shahidi et al. “Evaluation of the Efficacy of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” DiVito et al. “Evaluation of Intermediate-Range of Focus with New Monofocal Plus IOLs.” Lau et al. “Evaluation of the Safety of a Novel Preservative-Free Formulation of Brimonidine Tartrate Ophthalmic Solution.” Vollmer et al. “Impact of Pupil Size on Vision Performance of a New Multifocal Daily Disposable Contact Lens.” Reindel et al. “In-Home Use Test of a Novel Contact Lens Solution in Contact Lens Wearers on the Verge of Dropout.” Rah et al. “Intraocular Pressure Optimized Performance Settings with Posterior Adaptive Fluidics (PAF), and 25 Gauge 25,000 cpm Dual-Action Vitrectomy Cutters.” Papour et al. “Phaco Longitudinal Mode Heat Generation, a Two-System Efficiency Comparison Study.” Dickerhoff et al. “Preclinical Toxicity Pro Perfluorohexyloctane Ophthalmic Solution.” Vittitow et al. “Predictive Modeling of Clinical Performance of Novel Trifocal IOL.” Venkateswaran et al. About Bausch + Lomb Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on X, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “will,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2024 Bausch + Lomb.

02 Apr 2024

·www.biospace.com

Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials

A first-in-class product, QLS‑111 is designed to lower intraocular pressure (IOP) beyond currently achievable levels in patients with glaucoma by targeting episcleral venous pressure (EVP) DEDHAM, Mass.--(BUSINESS WIRE)-- Qlaris Bio, Inc. (“Qlaris”), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced the initiation and dosing of two separate U.S. Phase II masked, randomized clinical trials investigating QLS‑111 in patients with ocular hypertension and glaucoma. “The start of these Phase II trials represents a key milestone in our goal of bringing QLS‑111 to glaucoma patients for whom consistent IOP lowering and control has been an unachievable goal,” said Thurein Htoo, Chief Executive Officer. “IOP remains the only modifiable risk factor for the treatment of glaucoma, and additional treatments are needed for patients. QLS‑111 has the potential to change the treatment paradigm by effectively reducing IOP by lowering EVP, an unaddressed component of IOP.” Qlaris is initiating the following studies: The Osprey study (NCT06016972) will assess the safety, tolerability, and optimal dose of QLS‑111 compared with vehicle alone in adult patients who have primary open-angle glaucoma (POAG) and/or ocular hypertension (OHT). The efficacy of QLS-111 in lowering IOP will be assessed as a secondary endpoint of the trial. The Apteryx study (NCT06249152) will evaluate the safety and tolerability, and measure the additive IOP-lowering efficacy, of QLS‑111 in combination with latanoprost versus latanoprost alone. Patients aged 12 years or older and who have open-angle glaucoma (OAG) and/or OHT currently on latanoprost will be enrolled in the trial. “We are very pleased to initiate these studies in support of QLS-111 clinical development,” said Barbara Wirostko, MD, FARVO, Chief Medical Officer. “Despite the number of therapies currently available to clinicians, there remains a critical unmet need for new drugs that target unique parameters within IOP regulation with a strong safety profile. With a novel mechanism of action that targets EVP, as well as early data demonstrating it may be used in combination with existing treatments, QLS‑111 has the potential to make a significant impact.” QLS‑111 is an ATP-sensitive potassium channel modulator that is designed to reduce IOP by reducing EVP and distal outflow resistance, making it potentially suitable for treating POAG, OHT, and normal tension glaucoma (NTG). Current medications fall into two categories, those that reduce aqueous humor production and those that target proximal outflow. However, none of the current medications directly address distal outflow and EVP. This is important as EVP contributes up to 50% of total IOP, often leaving patients unable to reach IOP reduction goals to slow their disease progression, despite currently available therapies. QLS‑111's complementary mechanism may offer a significant and synergistic advantage in managing IOP. “I’m very excited about the promise of QLS‑111, which in healthy, normotensive volunteers lowered pressure significantly from baseline,” said Shan Lin, MD, Co-Research Director at the Glaucoma Center of San Francisco — a QLS‑111 investigational site — and a member of the Qlaris Scientific Advisory Board. “This suggests that QLS‑111 will benefit patients who do not adequately respond to currently available drugs due to the IOP floor set by EVP. Importantly, this compound has demonstrated that it can work alone or in combination with several current glaucoma drug classes, indicating that its use with current medications will aid in the ability to achieve levels of IOP reduction that slow disease progression. With its strong safety pro no clinically meaningful hyperemia, QLS‑111 holds enormous promise for our patients.” About QLS‑111 QLS‑111 is a novel topical formulation using Qlaris Bio’s ATP-sensitive potassium channel modulator platform originally developed by Dr. Michael Fautsch, PhD, professor of ophthalmology, biochemistry, and molecular biology at Mayo Clinic, in Rochester, Minnesota. QLS-111 lowers IOP by relaxing vessels of the vascular and vascular-like tissues distal to the trabecular meshwork, thereby reducing distal outflow resistance and lowering EVP. Though multiple mechanisms of action exist to lower IOP in patients with glaucoma, these agents target only three of the four components of IOP as described by the Goldman equation for IOP: the aqueous humor inflow rate, the uveoscleral outflow rate, and the conventional outflow facility. There are currently no approved drugs that selectively target the reduction of EVP. This leaves a significant gap in the potential to maximally lower IOP, since EVP can be the largest determinant of overall IOP. Studies have demonstrated that treatment with QLS‑111 provides persistent lowering of IOP, maintains normal vascular integrity of the venous system, is well-tolerated, and thus far has shown it does not cause hyperemia. About Qlaris Bio, Inc. Qlaris Bio, Inc. was founded in August 2019 with a singular focus: to develop novel, innovative therapies with first-in-class mechanisms of action to address serious and debilitating ophthalmic diseases. The company’s lead program, QLS‑111, uses ATP-sensitive potassium channel modulators that improve outflow through distal vascular tissues of the eye to reduce IOP. Qlaris Bio’s investors include Canaan and New Leaf Venture Partners, both of which were co-lead investors in the company’s $25 million Series A funding round in August 2019. Other investors include Correlation Ventures and Mayo Clinic, where the science behind QLS‑111 originated. For more information, please visit .

Phase 2

21 Mar 2024

·www.prnewswire.com

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income of RMB 246.4 million for the full year, a year-on-year increase of 55.0%; with a comprehensive gross profit of RMB 144.4 million, representing a year-on-year increase of 40.3%. During the reporting period, the company's major operating indicators performed well, benefiting from rapid growth in sales revenue and further improvement in operational efficiency and cost control. Enhanced Product Matrix, Rapid Expansion Leveraging First-mover Advantage Adhering to the development philosophy of "providing world-class holistic solutions for pharmaceuticals," OcuMension has consistently devoted itself to identifying, developing, and commercializing innovative or best-in-class ophthalmic therapies. The company continuously enriches and expands its product matrix to meet the significant demand gap in Chinese ophthalmic medical care while maintaining its leading position in the ophthalmic track. A diversified product matrix has laid the foundation for the company's steady growth. Leveraging its strong corporate strength, the company possesses a leading ophthalmic pharmaceutical platform with various drugs for both anterior and posterior segments, providing strong support for the company's development. Among them, the company's main products such as Ouqin (sodium hyaluronate eye drops), Emidin (timolol maleate eye drops), and Shilida (latanoprost eye drops) have all maintained steady growth. Additionally, as one of OcuMension's outstanding products, OT-401(YUTIQ)® for the treatment of chronic non-infectious uveitis was successfully included in the medical insurance catalog in December of last year. It is reported that OT-401(YUTIQ)® completed the first domestic injection in December 2022, breaking the deadlock in the treatment of uveitis in China at that time, filling the treatment gap domestically, alleviating the burden on patients to the greatest extent, and marking the formal entry of the product into ophthalmic clinical applications. It is worth noting that since OT-401(YUTIQ)® officially entered the medical insurance catalog on January 1st of this year, the company has rapidly promoted its medical insurance landing work nationwide with its comprehensive commercialization capabilities, bringing better and more affordable treatment options for uveitis patients. As of the disclosure date of the report, the terminal injection volume of OT-401(YUTIQ)® has exceeded the total for the previous year and is expected to continue to rapidly expand. Overcoming Technological Peaks, Strengthening Self-defense with R&D Strength To break the previous dominance of foreign capital in the Chinese ophthalmic drug market, the company continues to increase its investment in research and development, focusing on dual-source innovation, optimizing registration and development, promoting commercialization, and adhering to high-quality technical standards throughout the entire production cycle to ensure product safety, efficacy, and quality control. With years of technological accumulation and industrial experience, in 2023, the company achieved several milestone breakthroughs with the assistance of clinical PI, including the submission of NDA for OT-1001 (timolol hydrochloride eye drops) accepted by CDE and included in the priority review program; completion of global patient enrollment for Phase III MRCT of OT-101 (atropine sulfate eye drops); completion of real-world studies for OT-502 (dexamethasone implant), currently in the Pre-NDA stage; the completion of patient enrollment for Phase II clinical trials of OT-202 (tyrosine kinase inhibitor), a self-developed drug for dry eye syndrome, in 25 experimental centers, with a total of over 700 patients enrolled during the year. This not only enriches the company's product pipeline but also provides more high-quality treatment options for patients. The edge of technology stems from the strength of research and development behind it. Throughout 2023, the company invested a total of RMB 123.8 million in research and development, injecting strong momentum into the company's continued development. Meanwhile, the company also focuses on building a clinical research platform and constructing a research and development team to enrich the company's product pipeline and produce multi-level products that better meet patient needs. So far, the company has a total of 25 drug assets for both anterior and posterior segments, with 12 products already commercialized, covering both anterior and posterior segments and forming a strong product matrix in the fields of anti-allergy and glaucoma. Among them, five products in the company's pipeline are still in Phase III clinical trials, making it one of the companies with the highest number of Phase III clinical trials for innovative drugs in the Chinese ophthalmic drug market. It is noteworthy that the company has made breakthrough progress in the research and development of the myopia drug Atropine recently. Faced with the challenge of stability, the company cleverly solved the long-term storage stability problem of low-concentration atropine sulfate solution by using a dual-chamber device of reconstitution solution and freeze-dried powder. Currently, the company's self-developed product OT-101-S (0.01% and 0.05% atropine sulfate eye drops) has had its Phase III clinical trial application accepted by CDE in China. Accelerated Commercialization Process Provides Strong Support for Sales Revenue on the Sales Side As one of the powerful driving forces for terminal sales, commercialization has also shown remarkable performance for OcuMension in terms of product hospitalization. In 2023, with a complete product pipeline, the company continued to expand hospital coverage and accelerate product hospitalization. Currently, the company has formed a nationwide sales network, covering 1558 tertiary hospitals, with a commercial team of over 230 people. On this basis, the company deeply explores the commercial penetration of strong products such as Shilida and Emidin, achieving rapid growth in sales revenue. In addition, under the full play of national fiscal funds' guiding role in the development of innovative drugs, more approval resources will tilt towards high-value innovative drugs. With the company's increasingly mature commercialization process and the policy-driven tailwind, the company's image in the secondary market, previously underestimated, is expected to change. Within the month, the Hong Kong stock innovative drug sector has seen a full-scale increase, and the company gradually returned to a benign growth track in this round of valuation restoration of Hong Kong stock pharmaceuticals. In the future, driven by multiple factors such as aging, electronic lifestyle, increasing medical awareness among patients, and rising resident payment levels, China's ophthalmic market has tremendous development potential. The company will rely on its first-mover advantage to rapidly enhance its competitiveness and penetration in the domestic market, while actively expanding overseas markets to enhance the company's international influence. By continuously deepening hospital cooperation, optimizing sales network layout, the company will further improve product coverage, providing more patients with high-quality and efficient medical services. Chasing light and encountering, forging ahead. The development of innovative drugs in the field of Chinese ophthalmology is arduous but promising. With the continuous improvement in market recognition of the company's products, OcuMension will continue to uphold the development philosophy of innovation-driven and quality-oriented, continuously strengthen research and development investment, introduce more innovative and competitive products, strive to lead the market, and provide greater returns for investors. SOURCE OcuMension

Phase 3Financial StatementNDA

100 Deals associated with Latanoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D00356	Latanoprost	S01EE01	DB00654

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	JP	Viatris, Inc.	12 Mar 1999
Glaucoma, Open-Angle	US	Upjohn US 2 LLC	05 Jun 1996
Ocular Hypertension	US	Upjohn US 2 LLC	05 Jun 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dry Eye Syndromes	Preclinical	DE	Novaliq GmbH	15 May 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04133311 (CTgov)	Phase 3	Glaucoma, Open-Angle	386	DE-130A (DE-130A)	nrmwcicngn(lirtnorfen) = wpsgfavzlq zkriysabsc (nqgufqyidh, dazngzukmt - tbpyarools) View more	-	28 May 2024
				Xalatan® (Xalatan®)	nrmwcicngn(lirtnorfen) = obifxsoksr zkriysabsc (nqgufqyidh, dwnydijfjr - bflszpyiob) View more
ARVO2023	Not Applicable	Glaucoma	107	Preservative-free surfactant-free latanoprost eyedrop	wavmogiebf(ogxrrjcaeu) = tjipclldrg vjcqxzkqxv (amvlvyyfoz )	-	23 Apr 2023
ARVO2022	Not Applicable	-	-	Latanoprost	wvuadthety(afmyrikulz) = hosecgmmaz qrqhohireu (mzppmhjsku )	-	01 May 2022
				Latanoprost	wvuadthety(afmyrikulz) = fgvueqszcp qrqhohireu (mzppmhjsku )
NCT00934089 (CTgov)	Phase 2	Glaucoma, Open-Angle	31	Taprenepag+Latanoprost (Taprenepag+Latanoprost)	dfjfscrdye(egvzkmyyud) = bvwgkjpxet jchhblqxge (evmxrbujjf, errxsahbev - jesuhsbuhv) View more	-	03 May 2021
				Taprenepag+Latanoprost (Taprenepag+Latanoprost Vehicle)	dfjfscrdye(egvzkmyyud) = xwgfakgqqy jchhblqxge (evmxrbujjf, gmlixbqifg - okrpkrxjtp) View more
NCT02466399 (CTgov)	Phase 2	Glaucoma, Open-Angle	80	POLAT-001 (POLAT-001)	bevyxvqwsr(bztfyhghtw) = rrdxochysp nqxdnligju (uugbzpgmlj, bmmceclauy - dlrhzsrnlm) View more	-	16 Nov 2020
				Latanoprost ophthalmic solution (Latanoprost Ophthalmic Solution)	bevyxvqwsr(bztfyhghtw) = rkrqjdkelg nqxdnligju (uugbzpgmlj, dwsqmdhqld - rnxlsvoynd) View more
NCT00441883 (CTgov)	Phase 2	Glaucoma 1, Open Angle, A	176	PF-03187207 (PF-03187207 0.024% AM)	jfowatmpkl(nlmmejxqam) = uudtoxymtc mrjouvlcgv (txirjzzgcc, calhlrxdbi - nvyxgtgczk) View more	-	27 Aug 2020
				PF-03187207 (PF-03187207 0.040% AM)	jfowatmpkl(nlmmejxqam) = dzelbmythr mrjouvlcgv (txirjzzgcc, cxpeekfcwz - mbbomuosji) View more
NCT02017327 (CTgov)	Phase 4	Glaucoma, Open-Angle	379	Monoprost (Monoprost)	saquonfncq(akqpkoagnu): P-Value = 0.0045	-	02 Apr 2020
				Lumigan 0.01% (Lumigan 0.01%)
NCT02801617 (CTgov)	Phase 3	Glaucoma, Open-Angle	116	GAAP Ofteno®+PRO-067 (Sequence 1 (PRO-067))	yivxapzryj(qohhidvrdc): P-Value = 0.388	-	28 Oct 2019
				GAAP Ofteno®+PRO-067 (Sequence 2 (GAAP Ofteno®))
2019 ARVO Annual Meeting (ARVO2019)	Not Applicable	Stanniocalcin-1	6	Latanoprost-free acid (LFA)	cdxporzjvm(lsduynkdgy) = icraiibyvm pqbscvaonc (meozztosim )	Positive	01 Jul 2019
				Stanniocalcin-1 (STC-1)	cdxporzjvm(lsduynkdgy) = evusoatmur pqbscvaonc (meozztosim )
ARVO Annual Meeting 2019 (ARVO2019)	Not Applicable	Glaucoma	24	Latanoprost	lgztzpcwae(meftggsqzz) = acvinbzadv rkqzmvcuff (bevxkvsrrg ) View more	Positive	01 Jul 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis